Category Archives: Muscular Dystrophy Treatment

EDITOR'S NOTE: Please note that due to the ongoing COVID-19 pandemic, some of the following meetings/events may be cancelled or rescheduled unexpectedly. The Purple Heart Chapter of Sumter is sponsoring a project to have all Purple Heart medal recipients inducted into the National Purple Heart Hall of Honor located in New York. Continue reading →

-- MDA to offer Invitae's Detect Muscular Dystrophy program in 150 care centers -- SAN FRANCISCO, March 23, 2020 /PRNewswire/ --Invitae (NYSE: NVTA), a leading medical genetics company today announced its partnership with the Muscular Dystrophy Association (MDA) to offer sponsored, no-charge genetic testing to patients through the Detect Muscular Dystrophy program in MDA's care center network, a network of clinics at more than 150 of the nation's top healthcare institutions. Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people Continue reading →

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- CureDuchenne, the leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, is rolling out a comprehensive suite of online resources for the Duchenne community. This suite of resources is aimed at engaging the community to maintain continuity of care and community building in the current times of global health uncertainty: While the global coronavirus pandemic is experienced differently by everyone and most are confined to stay in their homes, the effect on individuals with Duchenne, their families and caregivers, carries greater weight due to the health complexities that Duchenne presents. Confinement requires new ways for families and caregivers to get access to resources they need and creativity to put those things at their fingertips Continue reading →

Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus LOS ANGELES, March 24, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced that it will host a Key Opinion Leader (KOL) call on why exosomes are uniquely suited for vaccine development on Thursday, March 26, 2020 at 12pm Eastern Time. The call will feature a presentation by KOL and newly appointed Capricor Executive Consultant Stephen J. Gould, Ph.D., from Johns Hopkins University, who will provide an overview of an exosome-based vaccine approach. Continue reading →

A shopping list for the dip If there's one thing lacking in the stock market these days, it's conviction. Long-term investors are likely looking for stocks to buy to take advantage of the market weakness, but they may not know which stocks are safe to start buying and which ones could still be headed much lower. Continue reading →

Pharmacia & Upjohn LLC The report offers an in-depth assessment of key market dynamics, the competitive landscape, segments, and regions in order to help readers to become better familiar with the Duchenne Muscular Dystrophy Treatment market. It particularly sheds light on market fluctuations, pricing structure, uncertainties, potential risks, and growth prospects to help players to plan effective strategies for gaining successful in the Duchenne Muscular Dystrophy Treatment market. Importantly, it allows players to gain deep insights into the business development and market growth of leading companies operating in the Duchenne Muscular Dystrophy Treatment market. Continue reading →

EDITOR'S NOTE: Due to the COVID-19 pandemic, some events/meetings may be canceled or rescheduled unexpectedly. The Purple Heart Chapter of Sumter is sponsoring a project to have all Purple Heart medal recipients inducted into the National Purple Heart Hall of Honor located in New York. An enrollment application must be completed by the medal recipient or next of kin if the veteran is deceased Continue reading →

Exosystems is a startup specializing in developing healthcare wearables and digital therapeutics, providing a new platform for a healthy life in this era of population aging. The company participated in Consumer Electronics Show (CES) 2020 with its wearable exoRehab, which provides rehabilitation training for people who have difficulty in walking due to muscular dystrophy from aging and the aftereffects of a stroke. Exosystems received two CES Innovation Awards Continue reading →

by Fiona Kellas, Reuben Jacob 16 March 2020 14:20 Reuben Jacob and Fiona Kellas, Maucher Jenkins share their expertise on IP strategies and considerations for gene therapy inventions. Gene therapy enables the treatment of a disorder or disease through the insertion of a gene into a patients cells instead of using drugs or surgery.This technique involves the introduction of genetic material into cells to compensate for abnormal genes in the patient or to make protein that will be beneficial to the patient.As an example, if a mutated gene causes a protein that is necessary for the correct functioning of cells to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein.Gene therapy is understood to be useful in the treatment of a range of conditions such as cancer, cystic fibrosis, muscular dystrophy and Alzheimers disease. UK role in gene therapy techR&D Gene therapy is considered to be very important to the future of medicine and as such, many companies are focussing their research and development into gene therapy technologies.The UK is a growing industry for research into these areas and it is anticipated that by 2035 the UK industry around cell and gene therapy technologies will be worth in the region of 10 billion.Gene therapy research is still at an early stage.Due to this length of time and the associated costs involved in developing an effective gene therapy and taking it through to approval, it will be important for companies working in this area to put into place an effective IP strategy that will provide protection for their inventions and assist them in maintaining their market position.In addition, the competitive nature of the gene therapy industry means that will be important for a company to obtain patent protection for inventions being developed, as well as reviewing the patent landscape to check that the company is free to operate in their chosen area. Continue reading →

SOUTH PLAINFIELD, N.J., March 2, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2019. "2019 was a year of outstanding execution for PTC. Continue reading →